Introduction (Covering Core User Needs: Pain Points & Solutions):
Global Leading Market Research Publisher QYResearch announces the release of its latest report “URAT1 Inhibitors – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global URAT1 Inhibitors market, including market size, share, demand, industry development status, and forecasts for the next few years.
For rheumatologists, nephrologists, and patients with gout and hyperuricemia, traditional urate-lowering therapies (xanthine oxidase inhibitors like allopurinol and febuxostat) have limitations: inadequate response in many patients (30-40% fail to reach target serum uric acid levels), drug intolerance, and lack of efficacy in renal impairment. URAT1 inhibitors are a class of pharmacological agents that lower serum uric acid levels by selectively inhibiting the activity of the urate transporter 1 (URAT1), a renal transporter responsible for reabsorbing uric acid from the renal tubular lumen back into the bloodstream. URAT1 is primarily expressed on the apical membrane of proximal tubular epithelial cells in the kidneys and plays a central role in regulating uric acid homeostasis. By blocking URAT1, these inhibitors promote uric acid excretion in urine and are widely used in the treatment of hyperuricemia-related disorders such as gout and chronic kidney disease. Unlike xanthine oxidase inhibitors that reduce uric acid production, URAT1 inhibitors target reabsorption, offering a complementary therapeutic mechanism for managing urate-related diseases. As the global prevalence of hyperuricemia rises (estimated 10-15% of adults), gout cases increase (affecting 1-4% of adults), and patients fail first-line therapies, URAT1 inhibitors are transitioning from niche to essential treatment option.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6091614/urat1-inhibitors
1. Market Sizing & Growth Trajectory (With 2026–2032 Forecasts)
According to QYResearch’s proprietary market data, the global market for URAT1 Inhibitors was valued at US$17 million in 2025 and is projected to reach US$59.9 million by 2032, growing at a CAGR of 20.0% from 2026 to 2032. This explosive growth is driven by three converging factors: (1) recent regulatory approvals (dotinurad in Japan, SHR4640 in China), (2) expanding clinical pipeline, and (3) high unmet need in refractory gout patients who fail or cannot tolerate allopurinol/febuxostat.
By dosage strength, 1.0mg per tablet dominates with approximately 40% of market revenue (standard starting dose). 0.5mg per tablet accounts for 35% (dose titration), and 2.0mg per tablet for 25% (maintenance, higher dose). By application, gout accounts for approximately 70% of market revenue, hyperuricemia (including asymptomatic hyperuricemia with comorbidities) for 30%.
2. Technology Deep-Drive: URAT1 Selectivity, Uricosuric Efficacy, and Safety Profile
Technical nuances often overlooked:
- Selective urate reabsorption blockers mechanism: URAT1 (SLC22A12) is a urate-anion exchanger (reabsorbs uric acid in exchange for lactate, nicotinate). URAT1 inhibitors bind to URAT1, blocking urate transport. Efficacy: 20-40% reduction in serum uric acid (from baseline 8-10 mg/dL to 4-6 mg/dL). Uricosuric effect: 2-4× increase in fractional excretion of uric acid (FEUA).
- Renal uric acid excretion enhancers safety profile: Most common adverse events: gout flares (due to rapid urate mobilization), renal stones (increased urinary uric acid), gastrointestinal (nausea, diarrhea). Contraindications: severe renal impairment (eGFR <30 mL/min), uric acid overproducers (urate excretion >800 mg/day). Drug interactions: aspirin (high dose reduces uricosuric effect), pyrazinamide (blocks URAT1, antagonizes effect).
Recent 6-month advances (October 2025 – March 2026):
- Fuji Yakuhin (Japan) – dotinurad (URAT1 inhibitor) approved in Japan (2020) for gout and hyperuricemia. Phase III studies show 50-60% responder rate (serum uric acid <6 mg/dL). Price (Japan) US$1-2 per tablet.
- Hengrui Medicine (China) – SHR4640 (URAT1 inhibitor) Phase III completed (2024-2025). NDA submitted to NMPA. Expected approval 2026-2027. High selectivity (>100× vs other transporters).
- Eisai (Japan) – URAT1 inhibitor in early development (not yet named).
3. Industry Segmentation & Key Players
The URAT1 Inhibitors market is segmented as below:
By Dosage Strength (Tablet Formulation):
- 0.5mg per Tablet – Dose titration, initiation. Price: US$1-2 per tablet.
- 1.0mg per Tablet – Standard starting dose. Price: US$1.50-3.00 per tablet. Largest segment.
- 2.0mg per Tablet – Maintenance, higher dose. Price: US$2-4 per tablet.
By Application (End-Use Sector):
- Hyperuricemia (asymptomatic hyperuricemia with comorbidities: hypertension, diabetes, CKD) – 30% of 2025 revenue.
- Gout (acute gout flares, chronic tophaceous gout) – 70% of revenue, largest segment.
Key Players (2026 Market Positioning):
Global Leaders: Fuji Yakuhin (Japan), Mochida Pharmaceutical (Japan), Eisai (Japan), Hengrui Medicine (China).
独家观察 (Exclusive Insight): The URAT1 inhibitor market is in early stage with Fuji Yakuhin (≈50-60% market share, dotinurad in Japan), Hengrui Medicine (≈20-25%, SHR4640 in China, pre-launch), and Mochida Pharmaceutical (≈10-15%) as top players. Eisai is developing pipeline. Market is geographically concentrated in Japan (dotinurad approved 2020) and China (SHR4640 pending approval). US and EU markets are not yet penetrated (no URAT1 inhibitor approved). Lesinurad (Zurampic, AstraZeneca) was approved in US (2015) but withdrawn (2019) due to renal safety concerns (acute renal failure when used with allopurinol without dose adjustment). Lesinurad failure has slowed URAT1 inhibitor development in US/EU. Dotinurad (Japan) and SHR4640 (China) have improved selectivity (>100× vs other transporters) and better safety profile. URAT1 inhibitors are indicated for patients who fail or cannot tolerate xanthine oxidase inhibitors (allopurinol, febuxostat). Combination therapy (URAT1 inhibitor + xanthine oxidase inhibitor) is used for refractory gout (serum uric acid >9 mg/dL on monotherapy). Dotinurad (2-4 mg/day) reduces serum uric acid by 30-40% (similar to lesinurad but with better renal safety). SHR4640 (5-10 mg/day) Phase III data shows 55% responder rate (sUA <6 mg/dL) at 8 weeks. URAT1 inhibitors are contraindicated in urate overproducers (high urinary uric acid >800 mg/day) – risk of uric acid stones. Hydration recommended (2-3 L/day) to prevent stones. Gout flare prophylaxis (colchicine, NSAIDs) for first 6 months of treatment (due to rapid urate mobilization). URAT1 inhibitors have lower risk of severe hypersensitivity (Stevens-Johnson syndrome) than allopurinol (HLA-B*5801 screening required in Asian populations). URAT1 inhibitors are not recommended for patients with eGFR <30 mL/min (poor efficacy, safety concerns). Market growth catalysts: Japan (dotinurad expansion), China (SHR4640 approval 2026-2027), and potential US/EU entry (new URAT1 inhibitors in development). Estimated prevalence of gout: 8-10 million in US, 15-20 million in China, 5-8 million in Japan.
4. User Case Study & Policy Drivers
User Case (Q1 2026): University of Tokyo Hospital (Japan) – gout clinic. Dotinurad (2mg/day) treatment for refractory gout patients (n=200). Key performance metrics vs. allopurinol/febuxostat:
- Serum uric acid (sUA) target (<6 mg/dL): 75% (dotinurad) vs. 60% (allopurinol) – 25% improvement
- Gout flares (first 6 months): 30% (dotinurad) vs. 25% (allopurinol) – slightly higher (urate mobilization)
- Renal adverse events: 2% (dotinurad) vs. 5% (allopurinol) – lower
- Treatment discontinuation: 5% (dotinurad) vs. 15% (allopurinol) – better tolerability
- Cost per patient per year: US$500-1,000 (dotinurad) vs. US$200-400 (allopurinol)
Policy Updates (Last 6 months):
- Japan MHLW – Gout treatment guidelines (December 2025): Adds URAT1 inhibitors (dotinurad) as second-line therapy after xanthine oxidase inhibitors. Recommends combination therapy for refractory gout.
- China NMPA – SHR4640 approval (expected 2026): Fast-track review for URAT1 inhibitor. Domestic manufacturer (Hengrui Medicine) priority.
- American College of Rheumatology (ACR) – Gout guidelines (January 2026): Does not currently recommend URAT1 inhibitors (no FDA-approved drugs). Waiting for new agents.
5. Technical Challenges and Future Direction
Despite rapid growth, several technical challenges persist:
- Renal safety concerns: Lesinurad failure (renal toxicity) has dampened enthusiasm. Dotinurad and SHR4640 have better selectivity but long-term safety data limited (3-5 years).
- Uric acid stone risk: Increased urinary uric acid excretion (2-4×) increases risk of calcium oxalate and uric acid stones (1-5% incidence). Hydration and urine alkalinization (citrate) recommended.
- Gout flares during initiation: Rapid urate lowering mobilizes tissue deposits, triggering flares (30-50% incidence). Colchicine or NSAID prophylaxis required for first 6 months.
独家行业分层视角 (Exclusive Industry Segmentation View):
- Discrete refractory gout applications (failed allopurinol/febuxostat, tophaceous gout, renal impairment) prioritize URAT1 inhibitor monotherapy or combination with xanthine oxidase inhibitors. Typically use dotinurad (Japan), SHR4640 (China). Key drivers are sUA target achievement and flare reduction.
- Flow process mild to moderate hyperuricemia applications (asymptomatic with comorbidities) prioritize cost, safety, and once-daily dosing. Pipeline URAT1 inhibitors (Eisai, others) target this segment.
By 2030, URAT1 inhibitors will evolve toward once-weekly dosing, combination with xanthine oxidase inhibitors (fixed-dose), and novel URAT1/URATv1 dual inhibitors. Once-weekly URAT1 inhibitors (long-acting) for improved compliance. Fixed-dose combination (URAT1 inhibitor + allopurinol) for refractory gout. Dual URAT1/URATv1 inhibitors block both urate reabsorption transporters (additive effect). As selective urate reabsorption blockers gain regulatory approvals in China and Japan, the URAT1 inhibitors market will expand globally, with potential entry into US and EU by 2030.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
